

# Francesca Lim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9685080/publications.pdf>

Version: 2024-02-01

7  
papers

41  
citations

2258059

3  
h-index

2053705

5  
g-index

7  
all docs

7  
docs citations

7  
times ranked

91  
citing authors

#	ARTICLE	IF	CITATIONS
1	CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6931.	4.1	3
2	Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective. <i>Journal of Medical Economics</i> , 2021, 24, 637-653.	2.1	9
3	Proven and unproven cell therapies – what we have learned so far?. <i>ISBT Science Series</i> , 2021, 16, 213-218.	1.1	2
4	Mobilization kinetics of peripheral blood stem cells with rescue plerixafor – real-world experience from a single center. <i>Leukemia and Lymphoma</i> , 2020, 61, 1740-1743.	1.3	0
5	A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 28-29.	1.4	9
6	Respiratory virus infection after allogeneic hematopoietic stem cell transplant in a tropical center: Predictive value of the immunodeficiency scoring index. <i>Transplant Infectious Disease</i> , 2017, 19, e12693.	1.7	18
7	Evaluation of Human Polyomavirus (BKV) – Specific T Cell Immune Reconstitution in Allogeneic Haematopoietic Stem Cell Transplant Recipients. <i>Blood</i> , 2011, 118, 3223-3223.	1.4	0